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Abstract
Background: Metformin influences insulin receptor signaling, which might interfere with the proliferation of
ovarian follicular structures and steroidogenesis. We hypothesize that reductions in glucose and insulin levels might
interfere with CYP-17 expression and histomorphological changes in an androgenized rat model. The aim of this
study was to analyze the effect of metformin on CYP-17 expression, follicular dynamics, and proliferative parameters
in neonatally androgenized female rats.
Methods: Thirty-six newborn rats were randomly allocated to the following three groups on the third day of life:
control (CG, n = 12), androgenized (GA, n = 12), and androgenized + metformin (GAmet, n = 12). The GA and GAmet
animals were administered 0.1 mL of testosterone propionate (1.25 mg/animal) diluted in castor oil (vehicle) in a single
dose; the CG rats received a subcutaneous injection of the vehicle in the dorsum. After 90 days, gavage treatment was
initiated, distilled water was administered to the CG and GA rats, and metformin (150 mg/kg) was administered to the
GAmet animals. The treatment was administered daily for six weeks. Following anesthesia, blood was drawn for
biochemical measurements, and the ovaries were removed for histological and immunohistochemical analyses of Ki67,
VEGFA and CYP17 expression. The glucose and insulin levels were also measured.
Results: The comparison of the GA and GAmet animals revealed that metformin decreased the weight as well as the
glucose and insulin levels, slowed the proliferation of the theca interna and interstitial cells, as evidenced by Ki-67 and
VEGF-A expression, and diminished CYP17 expression in the analyzed ovarian structures. In addition, metformin
reduced the number of degenerating follicles and interstitial cells and improved angiogenesis.
Conclusion: Metformin improves the carbohydrate metabolism, reduces proliferation, and decreases CYP-17
expression in the follicular structures of androgenized rats.
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Background
Polycystic ovarian syndrome (PCOS) is a common
endocrine disorder in women of reproductive age, but
its etiology remains unclear. PCOS might have mul-
tiple causes, and one possible cause might be related
to its association with hyperinsulinemia and insulin
resistance [1]. The genesis and pathophysiology of
these changes are known to be related to hyperandro-
genism [2]. Hyperinsulinemic insulin resistance acts
indirectly on oocyte competence and oocyte quality,
increasing the production of ovarian androgens and
decreasing the synthesis of hepatic sex hormone-
binding globulin (SHBG) [3].
In PCOS, insulin sensitivity is thought to regulate the
expression of glucose transporters in granulosa cells by
reducing glucose uptake within the oocyte, thereby also
reducing the resources available for energy metabolism
[3].The insulin receptor sensitizer substance acts as an
intracellular second messenger, regulating the activities
of insulin and glucose metabolism and transport [4] and
decreasing hyperandrogenism and insulin resistance in
PCOS women [5].However, the exact mechanisms
through which an increase in androgen levels leads to
ovulation disorder are not yet fully understood. There-
fore, the use of animal models is important to better
understand the actions involved [6].
Several animal models, including nonhuman primates,
sheep, and rodents, have been established to study
PCOS. However, a whole-animal model that mimics all
the features associated with human PCOS has not yet
been established [6, 7].An injection of testosterone pro-
pionate, if administered during the first days of life in
rats, leads to a state of permanent estrus and keeps the
vagina from opening, which might indicate a reduction
or absence of ovulation due to hormonal dysfunction
[8].This method is used to assess the effects of
androgens on follicular physiology [9] and changes in
carbohydrate metabolism [1]. High testosterone doses
increase the serine phosphorylation of insulin receptor
substrate-1, inducing insulin resistance and compensa-
tory hyperinsulinemia, which produce a metabolic
disturbance [10].The effects of this method during the
first days of life in an animal model are likely due to
epigenetic modifications.
The ovarian CYP complexes are important for ovarian
steroidogenesis. The CYP17a1 and CYP11a1 genes en-
code 17-α hydroxylase and 17,20-lyase, respectively, two
key enzymes involved in the synthesis and metabolism
of androgens as well as the cholesterol side-chain cleav-
age enzyme, P450 [10]. The end result is pregnenolone
conversion into androgen, primarily in the theca interna
[11].The induction of permanent estrus through insulin
administration increases CYP17 expression and serum
androgen levels in female rats and results in the
breakdown of the estrous cycle [12]. In our previous
work [8], we demonstrated that our PCOS rat model ex-
hibited elevated insulin levels, which could explain the
permanent cycle and the increase in androgen produc-
tion [12]. However, there are scarce data regarding the
ability of metformin to reverse this effect because previ-
ous studies primarily demonstrated the effect of the drug
on weight and the glucose/insulin ratio [8].
In rats, metformin improves ovarian function in ani-
mals with permanent androgen-induced estrus [13–15].
In our previous studies, the percentage of neonatally
androgenized rats with PCOS was approximately 50 and
10% become pregnant after metformin treatment. The
reason that fertility was restored in such a small number
of animals might be related to the disruption of ovarian
activity or to endometrial abnormalities. Therefore, our
study aimed to assess the effects of metformin on the
follicular dynamics, CYP-17 expression and proliferation
parameters in neonatally androgenized female rats.
Methods
Virgin adult female albino EPM-1-Wistar rats (Rattus
norvegicus albinus) aged 90 to 120 days from the Center
for the Development of Experimental Models (CEDEME,
UNIFESP-EPM), Federal University of São Paulo – Pau-
lista School of Medicine (UNIFESP-EPM), were used in
this study and handled according to ethical principles
for experiments. This project was approved by the Insti-
tutional Review Board of UNIFESP-EPM (No. 0351/11).
The animals were transported to and housed in the
animal laboratory of the Division of Histology and Struc-
tural Biology, Morphology Department, UNIFESP-EPM,
where they were confined to plastic cages with metal
grids. The animals were administered standard rations
(Labina-Purina) and water ad libitum and were main-
tained at a room temperature of 21 °C to 25°Cand a 12-
h light/dark cycle (lights on from 7 a.m. to 7 p.m.) with
artificial lighting from fluorescent lamps (40-watt
daylight model).
After acclimatization for approximately 15 days, the
animals were grouped for mating: two female rats for
each male rat. Each group was placed and housed in a
cage from 7 p.m. to 7 a.m. without water or food. The
following morning, the mating test developed by
Hamilton and Wolfe [16], which is based on the pres-
ence or absence of sperm in the vagina of the female
rats, was performed. If positive, the test day was
regarded as the beginning of pregnancy (first day).
Following parturition, newborn rats were separated by
sex on the third day of life according to the anogenital dis-
tance [17]. Thirty-six newborn female rats were selected
and housed together with their mothers, but the male
newborns were euthanized. On the third day of life, 24 fe-
male newborns were administered 0.1 mL of testosterone
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propionate diluted in castor oil (vehicle) (1.25 mg/animal)
via the dorsal subcutaneous route by inserting the needle
from the dorsal region to the cervical region [8, 18]. The
remaining 12 newborn female rats constituted the control
group and received only vehicle.
All female newborns were housed together with
their mothers while nursing (30 days) under the
environmental conditions described above. After this
period of nursing, the animals were separated into
groups of four rats per cage. After 90 days, a vaginal
smear was collected from each animal on four
consecutive days. The testosterone propionate-
treated animals exhibited a closed vagina, and their
vaginal smear test demonstrated that they were in
permanent estrus [18, 19].
The animals were allocated to the following
groups: control group (CG), 12 female rats that re-
ceived no medication and only 0.5 mL of distilled
water by oral gavage for six consecutive weeks;
androgenized group (GA), 12 female rats in perman-
ent estrus that were treated with testosterone propi-
onate and 0.5 mL of distilled water by oral gavage
for six consecutive weeks; and androgenized + met-
formin group (GAmet), 12 female rats in permanent
estrus that were administered testosterone propion-
ate followed by metformin by oral gavage for six
consecutive weeks. A total of 36 animals were used
in this study.
All GAmet animals were weighed before and after
the metformin treatment. The medication, 150 mg/kg
of metformin [7] prepared in diluted water, was intro-
duced into the stomach of each animal by gavage
with a gastric catheter [20]. The dose of metformin
was determined based on previous studies [8, 20].Va-
ginal smears were collected from the GAmet animals
[21] daily for six weeks, starting on the first day of
metformin use, to characterize the estrous cycle.
Afterward, the animals in the control group were
sacrificed during the proestrus phase, and the GAmet
animals were sacrificed at the time of vaginal opening
and proestrus phase. The other animals were sacri-
ficed at any time after the treatment because it was
impossible to collect vaginal smears.
Prior to sacrifice, the female rats were fasted for 12 h
and then intraperitoneally anesthetized with 15 mg/kg
Xylazine (Rompun®; Bayer, Brazil) and 30 mg/kg Keta-
mine (Ketalar®; Pfizer, Brazil). Each animal was immobi-
lized on a cork board. The thoracic wall was then
opened with a xiphopubic incision of the wall for intra-
cardiac collection of blood for the insulin and fasting
glucose measurements and removal of both ovaries. The
ovaries were immersed in 10% formaldehyde for fixation
and subsequent histologic processing using the method-
ology described by Michalany [22].
Insulin and glucose measurements
The fasting glucose levels were measured using the
hexokinase enzymatic method, and the insulin levels
were measured using the Coat-A-Count (Diagnostic
Products Corporation, LA, USA) method according to
the manufacturer’s instructions. The test was performed
using a solid-phase radioimmunoassay with iodine 1251
for quantitative measurement of the serum insulin levels.
The inter-assay precision was approximately 10.2% (co-
efficient of variation), and the intra-assay precision was
approximately 6.5% (coefficient of variation). The assay
sensitivity was 4.2 micro IU/mL [23].
Glucose/insulin ratio calculation
The glucose/insulin ratio was calculated using the fol-
lowing formula: fasting glucose (ng/mL)/fasting insulin
(ng/mL) X 10 [7].
For the calculations, the unit of glucose was converted
from mg/dL to ng/mL.
Morphological analysis
The ovaries from each animal were fixed in 10% buffered
formaldehyde for 24 h, dehydrated in increasing concen-
trations of ethyl alcohol, cleared in xylol, and embedded
in liquid paraffin in a 60 °C oven using the methodology
described by Michalany [22]. Subsequently, the blocks
were cut into 4-μm sections with a Leica microtome.
The sections were placed on slides and incubated in a
37 °C oven for 24 h. The slides were then stained with
hematoxylin-eosin and mounted in Entellan for histo-
morphometric and immunohistochemical analyses.
Histomorphometric analysis
Histomorphometry was conducted using a computer
coupled to a light microscope (Carl Zeiss, Weesp, The
Netherlands) and a high-resolution camera (AxioCam
MRC, Carl Zeiss). The Vision REL 4.6 (Carl Zeiss) image
analyzer program was used [24, 25]. Measurements were
collected using the Image lab-Softium™ software pro-
gram (São Paulo, Brazil).
Ten measurements from each slide were collected for
each animal. The ovaries were included, and sections
were cut from the central region to the outer boundary.
The structures of interest were measured in microns.
Histological quantification encompassed the following
items: (1) thickness of the surface epithelium (μm); (2)
number of antral follicles (No./10 fields); (3) number of
non-antral follicles (No./10 fields); (4) number of degen-
erating follicles (No./10 fields); (5) number of corpora
lutea (No./10 fields); and (6) number of interstitial cells
(No./area of 780 μm2).
The follicles were counted and classified according
to previously established criteria [26–28]. Two
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independent histologists who were blinded to the
groups counted the follicles.
The ovarian follicles were divided into three categor-
ies: non-antral, antral, and degenerating. The corpora
lutea were also counted.
Non-antral follicles were defined by the absence of the
antral cavity and characterized as primordial, primary,
secondary, or tertiary follicles [29]. The primordial fol-
licle exhibited a layer of squamous cells surrounding the
oocyte. The primary follicle exhibited an oocyte sur-
rounded by a layer of cuboidal granulosa cells. The sec-
ondary follicle exhibited two to eight layers of granulosa
cells and no antral cavity surrounding the oocyte. Ter-
tiary follicles displayed more than eight layers of granu-
losa cells and lacked an antral cavity [27].
The follicles with an antral cavity, regardless of their
size, were considered antral follicles. The degenerating
follicles exhibited pyknotic nuclei in the granulosa layer,
according to the categorization reported by Pedersen
and Peters [26]. The corpus lutea exhibited characteristic
luteal cells with a voluminous nucleus and vessels [30].
Two observers who were blinded to the groups separ-
ately collected the histomorphometric measurements.
Immunohistochemical analysis of the ovaries
The histological tissue sections were fixed in buffered 10%
formaldehyde for 24 h and then embedded in paraffin.
Sections with a thickness of 3 μm were cut on a Minot-
like microtome and placed on slides that had previously
been treated with 5% silane. The sections were subse-
quently incubated overnight in a solution with the follow-
ing antibodies: (1) anti-Ki67(1:200; Spring Bioscience
Corp.; [SP6]; M3060); (2) anti-VEGFA (1:200; Spring Bio-
science Corp.; [SP28]; M3281), and (3) anti-CYP17A1
(1:200; Santa Cruz Biotechnology; [C-17]; SC-46081). The
sections were then incubated with a secondary antibody
and a Dako kit (Dako LSAB + Sys, Peroxidase Universal
K0690–1). The sections were then washed and incubated
with a freshly prepared streptavidin-biotin immunoperoxi-
dase solution (LSAB Dako kit) according to the manufac-
turer’s instructions. After washing, the bound enzyme was
visualized after an additional incubation with the enzyme
in the presence of 1% 3,3′-diaminobenzidine (Dako
K3468–1). The negative control consisted of incubation
with non-specific goat antibodies at the same concentra-
tion as the primary antibody for each immunohistochemi-
cal reaction (Ki67, VEGF and CYP17A1). All the sections
were also stained with hematoxylin.
Using the protocol reported by Panzan et al. [31], the
results were categorized by applying a scoring system
based on the intensity of the reactions and the frequency
of stained cells. The presence of a brownish color in the
tissue was adopted as a positive reaction (i.e., binding of
the antigen to the primary antibody). Immunoexpression
was evaluated at 400× magnification using the semi-
quantitative method.
The percentages of stained epithelial cells were graded
as follows: 0% (grade 0), 1 to 25% (grade 1), 26 to 50%
(grade 2), 51 to 75% (grade 3), and 76 to 100% (grade 4)
of the cells in a representative area. The intensity of the
immunoreactions was scored as negative (0), mild (1),
moderate (2), or strong/intense (3). The sections with no
staining were deemed negative. The total index was cal-
culated using the following formula: Total index = per-
centage of immunopositive cells x immunoreaction
intensity. The results are expressed as scores ranging
from 0 to 12.
The expression of Ki67 antigen was determined as a
percentage (%) of positively stained cells. In all cases, at
least 500 cells in a 100-μm2 area were counted per animal.
The investigators were blinded to the group allocation.
Statistical analysis
The data are expressed as the means ± standard devia-
tions (M ± SD). The statistical analyses were performed
with GraphPad Prism 5.0® (GraphPad Software Inc.) soft-
ware. The distribution of the data was analyzed using
the Kolmogorov-Smirnov test. If the distribution was
normal, the data were analyzed by one-way ANOVA
followed by Tukey’s test, a procedure for analyzing vari-
ables with multiple comparisons. However, the Kruskal-
Wallis test and the Dunn post hoc test were employed
to analyze the immunohistochemical data, which did not
exhibit a normal distribution. Additionally, the correla-
tions of the glucose/insulin ratio and weight with the
CYP17 data of the glucose level with the weight were
assessed using Spearman rank correlation coefficients.
Statistical significance was attained if the p-value was
less than 0.05 (α < 5%).
Results
The fasting glucose levels, insulin levels, glucose/insulin
ratio, animals’ weights, and Spearman correlation be-
tween glucose levels and weight are presented in Fig. 1.
The GA rats presented higher glucose and insulin levels
and increased weight compared with the rats in the CG
and GAmet groups (p < 0.05) (Fig. 1a, b, and c). Addition-
ally, compared with the other groups, the GA rats exhib-
ited the lowest G/I ratio (p < 0.01) (Fig. 1d). No
correlation between the weight data and glucose levels
was identified using the Spearman test (Fig. 1e, f, g).
The histomorphometric data for the ovaries (Table 1)
showed that the GA rats have greater quantities of degener-
ating follicles and interstitial cells than the CG or GAmet
rats (p < 0.01). No significant difference was observed be-
tween the non-antral and antral follicles or in the thickness
of the ovarian surface epithelium among the three study
groups. Nevertheless, an absence of corpora lutea was
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observed in the GA rats, and the GAmet rats had fewer
corpora lutea than the CG rats (p < 0.01, Table 1).
As shown through Ki67, VEGFA and CYP17 immuno-
histochemistry analyses (Table 1 and Fig. 2), the expres-
sion of Ki67 was increased in the granulosa cells and
decreased in the theca interna cells and interstitial cells
of the GAmet animals compared with the GA animals
(p < 0.05). Compared with the CG animals, the expres-
sion of Ki67 in the GAmet animals was similar in the
three structures under consideration.
Fig. 1 Weight measurements and biochemical analysis. a Weight of the rats in the following groups: CG (control group), GA (androgen group),
and GAmet (metformin group). p = 0.049 (ANOVA and Tukey’s test). b GA rats exhibited the highest glucose values, *p = 0.038 (Kruskal-Wallis and
Dunn tests). c The insulin levels of the GA group were higher than those of the other groups, p < 0.01(Kruskal-Wallis and Dunn tests). d The
lowest glucose/insulin ratio was observed in the GA group, * p < 0.01. e Spearman rank test of the correlation of glucose with weight in CG rats
(no significant correlation). f Spearman rank test of the correlation of glucose with weight in GA rats (no significant correlation). g Spearman rank
test of the correlation of glucose with weight in GAmet rats (no significant correlation)
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VEGFA expression was reduced in the three structures
of interest in the GAmet animals compared with the GA
animals (p < 0.05). CYP17 was expressed at the lowest
levels in the granulosa cells from the GA rats (p < 0.05)
and at the highest levels in the theca interna and intersti-
tial cells from the GA rats (p < 0.05, Table 1 and Fig. 2).
Graphical representations of the correlation between
the weight data and CYP17 expression in thecae cells
and between the glucose/insulin ratio and CYP17 ex-
pression in theca cells are presented in Fig. 3. No correl-
ation was observed between the weight data and CYP17
expression in any of the groups or analyzed structures
(granulosa, theca and interstitial cells). We observed sig-
nificant correlations between the expression in theca
interna cells and the glucose/insulin ratio in the GA rats
(r = − 0.81, p = 0.001) and the GAmet rats (r = − 0.61, p
= 0.03). No correlation was observed between the granu-
losa or interstitial cells and CYP17 expression in the
control group.
Discussion
The effects of metformin on insulin metabolism have been
previously evaluated [32]. However, the effects of this drug
on the reproductive system, particularly the ovaries, is not
well understood [3]. Here, we found that metformin par-
tially restored the follicular dynamics with an increase in
the number of luteal bodies and intense decreases in
androgen-induced proliferation of thecae cells and CYP-
17 expression, which is responsible for steroidogenesis
and the maintenance of androgen production [12, 18, 33].
These effects restore the normal morphology of ovaries
[34–37], but the aim of our study was not to observe the
effect of metformin on the atresia of follicles. Further
study is necessary to test this hypothesis.
In the study conducted by Shah and Patel [20], the
androgenized rats exhibited a significant increase in
CYP 17A1 expression in ovarian theca cells compared
with the normal group, and the insulin levels were in-
creased significantly. Treatment with metformin pro-
duced a significant decrease in the insulin levels [19, 38].
The results from another animal model using dehydro-
epiandrosterone to induce conditional hyperandrogenic
PCOS demonstrated that treatment with metformin re-
stored the percentage of endothelial and periendothelial
cells and the level of ovarian VEGF [33]. Metformin also
normalized the insulin concentration in PCOS rats and
improved follicular development [33, 39]. These results
suggest that metformin regulates vascular formation and
Table 1 Ovary histomorphometry and VEGFA, Ki67 and CYP17 immunohistochemical data of the study groups
Variable CG (n = 12) GA (n = 12) GAmet (n = 12)
Degenerating follicles
(No./slide)
4.11 ± 1.07 5.87 ± 1.87* 3.10 ± 1.10
Corpora lutea (No./10 fields) 8.26 ± 2.81** – 3.06 ± 1.32
Non-antral follicles
(No./10 fields)
3.23 ± 1.41 5.98 ± 3.88 3.77 ± 2.80
Antral follicles (No./fields) 1.97 ± 1.87 2.89 ± 1.89 2.98 ± 1.95
Interstitial cells
(No./780-μm2 area)
162.29 ± 23.21 313.18 ± 26.38* 172.45 ± 37.85
Epithelial thickness (μm) 8.28 ± 0.10 8.59 ± 0.19 8.30 ± 0.15
VEGFA (index)
Granulosa cells 2.6 ± 0.2 9.6 ± 0.3* 4.2 ± 0.6
Theca interna cells 3.8 ± 0.2 10.7 ± 0.6* 5.1 ± 0.2
Interstitial cells 2.6 ± 1.6 9.3 ± 0.3* 4.2 ± 0.2
Ki67 (%)
Granulosa cells 32.0 ± 4.4 14.0 ± 3.3* 28.1 ± 2.5
Theca interna cells 16.0 ± 2.2 34.0 ± 1.5* 18.0 ± 3.1
Interstitial cells 1.2 ± 0.1 8.0 ± 0.3* 1.1 ± 0.4
CYP17 (%)
Granulosa cells 1.1 ± 0.8 1.5 ± 1.1 1.2 ± 0.9
Theca interna cells 5.5 ± 1.7 9.3 ± 1.2* 6.2 ± 0.7
Interstitial cells 5.2 ± 0.8 7.4 ± 1.4* 4.2 ± 1.6
Abbreviations: CG control group, GA androgenized group, GAmet androgenized + metformin group. The data for all the groups are presented as the means
±standard deviations. The histological results were analyzed using analysis of variance (ANOVA) and Tukey’s test. The VEGFA, Ki67 and CYP17
immunohistochemical data were analyzed using the Kruskal-Wallis test and the Dunn test. *p < 0.01 compared with the other groups and **p < 0.05 compared
with the GAmet group
Mahamed et al. Journal of Ovarian Research  (2018) 11:18 Page 6 of 10
Fig. 2 Photomicrographs of ovary sections immunostained for VEGFA (a, b, c); note the higher level of staining in the inner theca and granulosa
cells in the GA group (b). Ki67 (e, f, g) staining was highest in the inner theca of the GA group (f) and lowest in the granulosa cells of the control
group (e). CYP17 (i, j, k) expression was highest in the inner theca of the GA (j) group and in the granulosa cells of the control group (i). d, h,
and l are negative controls for VEGFA, Ki67 and CYP17, respectively. Arrows: inner theca; asterisks: granulosa cells. Bars = 20 mm;
magnification × 400
Fig. 3 Graphical representations of the Spearman rank test for the correlation of the weight data withCYP17 expression in thecae cells of the (a)
CG group (control group, no correlation), (b) GA group (androgen group, no correlation), and (C) GAmet group (metformin group, no
correlation). d–f show graphical representations of the correlations between the glucose/insulin ratio data and CYP17 expression in theca cells. d
CG, no correlation, (e) GA, significant correlation (r = − 0.81, p = 0.001), and (f)GAmet, significant correlation (r = − 0.61, p = 0.03)
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stability in developing ovarian follicles from DHEA-
treated rats. Metformin reduced the higher VEGF ovar-
ian concentration. However, the researchers did not
correlate the glucose/insulin ratio with the expression of
CYP-17. In our study, we found that decreased CYP-17
was correlated with a low glucose/insulin ratio, which
might reflect the insulin resistance detected in our
animal model.
Hyperinsulinemia and hyperandrogenism are closely
related [40, 41]. In fact, increased insulin levels are an
important factor for the maintenance of hyperandrogen-
ism. Together with luteinizing hormone (LH), insulin
directly affects androgen production by increasing the
androgen levels in theca interna cells in the ovaries in
animal models [8, 12, 20]. Hence, the histological and
immunohistochemical changes observed in our study
might be associated with insulin metabolism, particularly
in relation to CYP17 activity in theca interna cells. Met-
formin might reverse the effects of androgens on neo-
natal female rats through this mechanism and by
modulating the insulin levels [20].
The mechanism of action of metformin involves
AMPK in the insulin receptor signaling pathway [3]. Cell
culture experiments have demonstrated that metformin
directly inhibits rat ovarian theca-interstitial cell prolifer-
ation through AMPK [40, 42]. This action might explain
the decrease in KI-67 and VEGF levels in theca cells ob-
tained after metformin treatment in our animals. Met-
formin might indirectly decrease the production of liver
growth factors, which might act on the ovaries [34, 41].
In our model, the number of IGF-1 receptors is de-
creased in granulosa cells and increased in theca interna
cells, thus contributing to an increase in hyperandrogen-
ism [35, 43]. Additionally, at high non-physiological con-
centrations, insulin binds to IGF-1 receptors, but if
these receptors are blocked or reduced in number, insu-
lin binds to the IGF-1 receptors on theca cells, thereby
activating the receptors, which then increase androgen
production [35]. Consequently, a reduction in insulin de-
creases CYP-17 expression and increases androgen pro-
duction. Androgens, in turn, also lead to insulin
resistance, particularly when administered to female rats
during the prenatal period [36]. This fact might explain
the higher glucose/insulin ratio values observed in the
animals that were not treated with metformin in this
study and that were previously reported [8].
VEGFA is an important agent involved in follicular
growth and maturation, ovulation, and the development
and maintenance of the corpus luteum [39]. Excess
VEGFA levels might be related to ovarian hyperstimula-
tion and the formation of multiple ovarian cysts. In our
study, VEGF expression was altered following metformin
administration to androgenized animals. In fact, metfor-
min affects the regulation of angiogenesis and prevents
excessive vascularization related to VEGF action, as
demonstrated in the study conducted by di Pietro et al.
[33]. In their study, female rats were androgenized with
dehydroepiandrosterone (DHEA) and then treated with
metformin, and the results were similar to those ob-
tained in our model. VEGF is also sensitive to the insulin
levels. Thus, the decreased insulin levels might justify
the lower VEGF levels observed in the ovary [20, 44, 45].
Metformin is important in both ameliorating the glu-
cose/insulin ratio in androgenized animals and improv-
ing ovarian follicular dynamics and enzymatic activity
(CYP-17). Other insulin sensitizers, such as inositol,
which re-establishes hormonal and metabolic parameters
to the homeostatic levels, have been recently introduced
and may have similar effect to metformin [46, 47].
The data reported in this manuscript were obtained
from animal models and are not applicable to daily med-
ical practice. This is a limitation of this study. Another
limitation is that we did not evaluate liver function, not-
ably the determination of IGF-1 and its binding proteins.
Thus, there is a need for additional studies to verify the
effects observed in this study, and further in vitro studies
are needed to investigate the mechanisms through which
metformin exerts its effects.
Conclusions
The effects of metformin on follicular cells and on CYP-
17 expression in testosterone-androgenized female rats
included improvements in the glucose levels and
changes to proliferation and ovarian steroidogenesis in
androgenized rats.
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